Drug intelligence / Profile preview

mTOR selective inhibitor

Development stage: Preclinical
Lead developer: TORQUR
Modality: Small Molecules
Administration: Oral, Topical

Overview

mTOR selective inhibitor is a preclinical-stage small molecule being developed by TORQUR. It is designed to selectively inhibit the mechanistic target of rapamycin (mTOR), a central regulator of cell growth, proliferation, and survival. By focusing on mTOR selectivity, the compound aims to provide a more targeted therapeutic effect compared to dual PI3K/mTOR inhibitors or non-selective mTOR inhibitors, potentially reducing off-target toxicities. The program is currently in the preclinical phase, with specific therapeutic indications yet to be disclosed by the company.

Other names: mTOR Selective InhibitorTORQUR-mTOR-small molecule

Targets

mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on mTOR selective inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mTOR selective inhibitor.

Explore the full profile